Clinical Trial Update: Glofitamab With Obinutuzumab, Venetoclax, and Lenalidomide for the Treatment of Patients With Newly Diagnosed High Risk Mantle Cell Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating a quadruple regimen of glofitamab, obinutuzumab, venetoclax, and lenalidomide for newly diagnosed high-risk mantle cell ly…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Blastoid Variant Mantle Cell Lymphoma
• Mantle Cell Lymphoma
• Pleomorphic Variant Mantle Cell Lymphoma

Drugs mentioned

• Glofitamab (glofitamab)
• Lenalidomide (lenalidomide)
• Obinutuzumab (obinutuzumab)
• Venetoclax (venetoclax)

Snippet

Sponsor: City of Hope Medical Center | Conditions: Blastoid Variant Mantle Cell Lymphoma, Mantle Cell Lymphoma | Phase 1, Phase 2 | Status: RECRUITING